Could a contraceptive gel ward off vaginal infections?
NCT ID NCT05753813
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tests whether a lactic acid gel (Phexxi) used twice weekly can change the vaginal microbiome to help prevent recurrent bacterial vaginosis and yeast infections. 22 premenopausal women with a history of these infections will use the gel for 4 weeks. Researchers will track changes in vaginal bacteria and symptoms.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- lactic acid gel (Phexxi)
- What this could lead to
- If it works, this could point toward a non-antibiotic way to prevent recurrent vaginal infections by boosting healthy bacteria.
- What could go wrong
- This is a very early, small study with only 22 people. It may not show a clear benefit, and results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Early phase 1
The earliest testing in people: a first look at safety, in a very small group.
- Participants
-
About 22 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 54 years
- Sex
-
Female participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18-54 * Female * Pre-menopausal * Can speak and read in English * Displays capacity for informed consent * Has had 2 or more documented and/or self-reported episodes of symptomatic BV or candida infection in the last year, requiring, over-the-counter or prescription treatment Exclusion Criteria: * Pregnant or trying to become pregnant * Post-menopausal * Using NuvaRing device * A past medical history of kidney disease, recurrent UTI, and/or urinary tract abnormalities * Current UTI * Using Phexxi as a contraceptive during the collection period of the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bacterial vaginosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Queens Medical Center, 1004 Clinic POB1
RECRUITINGHonolulu, Hawaii, 96813, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could women test for yeast infections at home? a swab test takes on the lab
- Zinc gel may outsmart recurring yeast infections
- Friendly bacteria vs. vaginal infections: a new trial puts probiotics to the test
- Can we finally outsmart recurrent yeast infections? a new study investigates
- Can a simple Self-Test cut preterm births in High-Risk pregnancies?
- Friendly bacteria vs. yeast: can a probiotic stop infections from coming back?